Fig 2: ADAM10 expression is upregulated in senescent cells. (A) IMR-32 cells were treated with 2 µM MLN8237, 0.5 µM DOX, DMSO, or no treatment as a control. Cell samples were collected at 24, 48, and 72 h. (B) Western blot and qRT-PCR analyses of ADAM10. (C) IMR-32 cells were treated with 2 µM MLN8237 or 0.5 µM DOX for 72 h, with no treatment was used as a control. Immunofluorescence detection of ADAM10 expression (magnification: ×20). Data represent the mean ± SEM of three independent experiments. *p < 0.05.

Fig 3: The MALAT1/miR-92a-3p axis regulates ADAM10 expression. (A) IMR-32 cells were treated with 2 µM MLN8237, 0.5 µM DOX, DMSO, or no treatment as a control. (B) After 72 h, miR-92a-3p and ADAM10 expression was detected by qRT-PCR. (C) Prediction of binding sites between miR-92a-3p and MALAT1 and those between miR-92a-3p and ADAM10 using ENCORI. (D) Confirmation of miR-92a-3p binding to ADMA10 and MALAT1 was confirmed by luciferase-reporter assay using 293T cells. (E) IMR-32 was co-transfected with an miR-92a-3p inhibitor and si-MALAT1, and ADAM10 level was detected by western blot. (F) The expression of miR-92a-3p and ADAM10 was detected by qRT-PCR. Data represent the mean ± SEM of three independent experiments. *p < 0.05.